{
    "clinical_study": {
        "@rank": "61905", 
        "arm_group": [
            {
                "arm_group_label": "MK-8457", 
                "arm_group_type": "Experimental", 
                "description": "MK-8457 administered orally at a dose of 100 mg twice daily (BID) for 24 weeks in the base study and an additional 76 weeks in the safety extension study; for a combined total of 100 weeks of treatment."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matching placebo to MK-8457 administered orally BID."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety and efficacy of MK-8457 in participants\n      with active rheumatoid arthritis (RA) and an inadequate response or intolerance to\n      anti-tumor necrosis factor \u03b1 (anti-TNF-\u03b1) therapy. The primary hypothesis of this study is\n      that among participants with active RA,  MK-8457 100 mg twice daily (BID) will be superior\n      to placebo as measured by the change in Disease Activity Score 28 C-Reactive Protein\n      (DAS28-CRP) after 12 weeks of treatment."
        }, 
        "brief_title": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Participants With Rheumatoid Arthritis (MK-8457-010)", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study consists of a 24-week base study in which participants will receive MK-8457 100\n      mg twice daily or matching placebo, and a 76-week safety extension in which participants\n      will receive MK-8457 100 mg twice daily."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of rheumatoid arthritis for at least 6 months prior to screening\n\n          -  Active rheumatoid arthritis as defined by the presence of >= 6 swollen joints (of 66\n             count) and >= 6 tender joints (of 68 joint count)\n\n          -  C-reactive protein blood level >0.9 mg/dL or an elevated erythrocyte sedimentation\n             rate (ESR) >28 mm/hr and evidence of synovitis on imaging\n\n          -  American College of Rheumatology Functional Class I, II, or III\n\n          -  Received methotrexate for a minimum of 3 months prior to screening with a regionally\n             appropriate stable weekly dose for at least 4 weeks prior to screening. The dose of\n             methotrexate must remain stable through Week 24 of the study.\n\n          -  Failed treatment with 1 or 2 anti-tumor necrosis factor alpha (anti-TNF-\u03b1) therapies\n             or was intolerant to anti-TNF-\u03b1 therapy prior to screening\n\n          -  If using non-steroidal anti-inflammatory drugs or other analgesics, participant must\n             be on a stable dose\n\n          -  No history of either untreated latent or active tuberculosis (TB) prior to baseline\n\n          -  Participants of reproductive potential must agree to remain abstinent or use 2\n             acceptable methods of birth control\n\n        Exclusion Criteria:\n\n          -  Presence of inflammatory disease other than rheumatoid arthritis, including but not\n             limited to psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus,\n             or Lyme disease\n\n          -  Hospitalization due to an acute cardiovascular event, cardiovascular illness, or\n             cardiovascular surgery within 6 months of screening\n\n          -  Participant has a transplanted organ, excluding corneal transplant, performed > 3\n             months prior to the first dose of trial medication\n\n          -  History of, or current ongoing ,chronic or recurrent infectious disease\n\n          -  Positive hepatitis B surface antigen or hepatitis C test result\n\n          -  Human immunodeficiency virus (HIV) positive\n\n          -  User of recreational or illicit drugs or has had a history (within the previous 2\n             years) of drug or alcohol abuse or dependence\n\n          -  Prior exposure to fostamatinib or other spleen tyrosine kinase inhibitors\n\n          -  Prior exposure to 3 or more anti-TNF therapeutic agents\n\n          -  Has been treated for RA with a marketed biologic agent  (other than anti-TNF\n             therapeutic agents) and failed the agent due to lack of efficacy\n\n          -  Currently participating in another interventional clinical trial or has participated\n             in an interventional clinical trial within 4 weeks prior to screening\n\n          -  Severe opportunistic infection within the 6 months prior to screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "56", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01651936", 
            "org_study_id": "8457-010", 
            "secondary_id": "2012-002181-12"
        }, 
        "intervention": [
            {
                "arm_group_label": "MK-8457", 
                "description": "MK-8457 administered orally at a dose of 200 mg daily.", 
                "intervention_name": "MK-8457", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "MK-8457", 
                    "Placebo"
                ], 
                "description": "Participants will continue on the stable dose of MTX that they were receiving prior to study entry.", 
                "intervention_name": "Methotrexate (MTX)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Rheumatrex", 
                    "Trexall"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Matching placebo to MK-8457 administered orally.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Methotrexate"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "October 25, 2013", 
        "number_of_arms": "2", 
        "official_title": "A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Worldwide, Proof-of-Concept Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Subjects With Active Rheumatoid Arthritis and an Inadequate Response or Intolerance for Anti-TNF-\u03b1 Therapy", 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change From Baseline in the Disease Activity Score 28 C-Reactive Protein (DAS28-CRP) at Week 12", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Week 12"
        }, 
        "removed_countries": {
            "country": [
                "United States", 
                "Australia", 
                "Colombia", 
                "Denmark", 
                "France", 
                "Greece", 
                "Italy", 
                "Hungary", 
                "Korea, Republic of", 
                "New Zealand", 
                "Poland", 
                "South Africa", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01651936"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of Participants Achieving American College of Rheumatology 20 (ACR20) Response at at Week 12", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "measure": "Proportion of Participants Achieving ACR20 Response at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "measure": "Proportion of Participants Achieving ACR50 Response at Week 12 and Week 24", 
                "safety_issue": "No", 
                "time_frame": "Week 12, Week 24"
            }, 
            {
                "measure": "Change From Baseline in DAS28-CRP at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 24"
            }, 
            {
                "measure": "Change From Baseline in the Health Assessment Questionnaire (HAQ) at Week 12 and Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12, Week 24"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}